– USA, CA – Arcus Biosciences, a clinical stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the appointment of David Beier, J.D. to its Board of Directors.
Mr. Beier brings extensive experience in the biopharmaceutical industry, particularly in areas such as healthcare policy, government affairs, regulatory affairs, pricing, healthcare economics and product commercialization. He is currently a Managing Director at Bay City Capital, where he has been since 2013. He also serves as an appointee of Governor Brown on the California State Government Organization and the Economy Commission. In addition, Mr. Beier is an advisor to the Parker Institute for Cancer Immunotherapy.
Previously, Mr. Beier served in the White House as Chief Domestic Policy Advisor to Vice President Gore during the Clinton Administration. He served as an appointee of President Clinton on his Advisory Committee for Trade Policy and Negotiations, on the Institute of Medicine panel on the Future of Health and Human Services, and as an advisor to the President’s Council of Advisors on Science and Technology. Mr. Beier was formerly a partner at Hogan and Hartson and Counsel to the U.S. House of Representatives Committee on the Judiciary.
Mr. Beier’s industry experience includes 9 years at Genentech as Vice President, Government Affairs and Policy as well as over 10 years at Amgen as Senior Vice President, Global Government Affairs and Corporate Affairs, where he had responsibility for public policy, coverage and reimbursement, payor planning, healthcare economics, communications and philanthropy.
“We are delighted to have David join our Board of Directors,” said Terry Rosen, CEO of Arcus. “David brings incredibly deep and invaluable experience in healthcare policy and economics that will be critical as we develop and prepare to commercialize our next generation immuno-oncology product candidates. Having spent many years at both Genentech and Amgen during periods of significant growth, he will be instrumental in helping to guide Arcus through the ongoing expansion of our organization and infrastructure. Due to his ongoing advisory role at the Parker Institute for Cancer Immunotherapy, he also brings highly relevant knowledge of the clinical development environment for immunotherapies.”
Mr. Beier commented, “Arcus has rapidly established itself in the field of immuno-oncology with two product candidates already in clinical trials and another two in IND-enabling studies, despite its formation only two years ago. I’m excited to work closely with the company as they focus on advancing their product candidates through clinical development and prepare for potential future commercialization in an exciting, and rapidly evolving field.”
About Arcus Biosciences
Arcus Biosciences is a clinical stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus was founded in 2015 by Terry Rosen and Juan Jaen, the co-founders of Flexus Biosciences, which was acquired by Bristol-Myers Squibb in 2015 to access Flexus’s IDO inhibitor, which was in preclinical development at the time and is now referred to as BMS-986205. Arcus has several programs targeting important immuno-oncology pathways, including a potentially best-in-class dual adenosine receptor antagonist and an anti-PD-1 antibody, both of which are in Phase 1 trials, as well as a potentially first-in-class small molecule inhibitor of CD73 and an anti-TIGIT antibody, which are in IND-enabling studies. Arcus has approximately 80 employees with extensive expertise in medicinal chemistry, immunology, biochemistry, pharmacology, and structural biology. The company is based in Hayward, CA.
For more information : http://www.arcusbio.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.